Allergen-specific Immunotherapy for Inhalant Allergens in Children

Author(s): Carlo Caffarelli, Jessica Cangemi, Carla Mastrorilli, Arianna Giannetti, Giampaolo Ricci*

Journal Name: Current Pediatric Reviews

Volume 16 , Issue 2 , 2020


Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Allergen-specific immunotherapy (AIT) for aeroallergens consists of the administration of standardized allergen extracts to patients with respiratory IgE-mediated diseases to the same allergen in order to achieve immune tolerance to the allergen and prevent the onset of symptoms. AIT is usually delivered by sublingual (SLIT), subcutaneous (SCIT) route. AIT with one or multiple allergens currently represents the only causal treatment able to change the natural history of allergic airway diseases. Significant progresses have been made in terms of AIT efficacy and safety.

In this paper, mechanisms of action, indication and side effects of allergen immunotherapy are reviewed.

SLIT and SCIT have been found to be effective in the treatment of asthma and rhinoconjunctivitis due to inhalant allergens. The route of AIT administration should be selected on availability, cost (dependent from the local health system), tolerability (better for SLIT), patient’s preference (injections are less accepted in young children), and adherence (higher for SCIT beyond pediatric age). However, it should be taken into account that metanalyses on AIT do not consider that effectiveness and safety depend upon the product chosen for treatment. Each product should be separately assessed to avoid generalization on administration routes or age group that may affect the decision.

Keywords: Asthma, children, immunotherapy, allergic rhinitis, allergen-specific immunotherapy, SLIT, SCIT.

[1]
Roberts G, Pfaar O, Akdis CA, et al. EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis. Allergy 2018; 73(4): 765-98.
[http://dx.doi.org/10.1111/all.13317] [PMID: 28940458]
[2]
Noon L. Prophylactic inoculation against hay fever. Lancet 1911; 177: 1572-3.
[http://dx.doi.org/10.1016/S0140-6736(00)78276-6]
[3]
Freeman J. Further observations on the treatment of hay fever by hypodermic inoculations of pollen vaccine. Lancet 1911; 178: 814-7.
[http://dx.doi.org/10.1016/S0140-6736(01)40417-X]
[4]
Scadding GK, Brostoff J. Low dose sublingual therapy in patients with allergic rhinitis due to house dust mite. Clin Allergy 1986; 16(5): 483-91.
[http://dx.doi.org/10.1111/j.1365-2222.1986.tb01983.x] [PMID: 3536171]
[5]
Jutel M, Agache I, Bonini S, et al. International consensus on allergy immunotherapy. J Allergy Clin Immunol 2015; 136(3): 556-68.
[http://dx.doi.org/10.1016/j.jaci.2015.04.047] [PMID: 26162571]
[6]
Calderón M, Cardona V, Demoly P. One hundred years of allergen immunotherapy European Academy of Allergy and Clinical Immunology celebration: review of unanswered questions. Allergy 2012; 67(4): 462-76.
[http://dx.doi.org/10.1111/j.1398-9995.2012.02785.x] [PMID: 22309435]
[7]
Quirt J, Hildebrand KJ, Mazza J, Noya F, Kim H. Asthma. Allergy Asthma Clin Immunol 2018; 14(Suppl. 2): 50.
[http://dx.doi.org/10.1186/s13223-018-0279-0] [PMID: 30275843]
[8]
James C, Bernstein DI. Allergen immunotherapy: an updated review of safety. Curr Opin Allergy Clin Immunol 2017; 17(1): 55-9.
[http://dx.doi.org/10.1097/ACI.0000000000000335] [PMID: 27906697]
[9]
Ciprandi G, Fenoglio D, Cirillo I, et al. Sublingual immunotherapy: an update on immunologic and functional effects. Allergy Asthma Proc 2007; 28(1): 40-3.
[http://dx.doi.org/10.2500/aap.2007.28.2974] [PMID: 17390756]
[10]
Tosca MA, Licari A, Olcese R, Marseglia G, Sacco O, Ciprandi G. Immunotherapy and asthma in children. Front Pediatr 2018; 6: 231.
[http://dx.doi.org/10.3389/fped.2018.00231] [PMID: 30186823]
[11]
Cuppari C, Leonardi S, Manti S, et al. Allergen immunotherapy, routes of administration and cytokine networks: an update. Immunotherapy 2014; 6(6): 775-86.
[http://dx.doi.org/10.2217/imt.14.47] [PMID: 25186606]
[12]
Nolte H, Maloney J. The global development and clinical efficacy of sublingual tablet immunotherapy for allergic diseases. Allergol Int 2018; 67(3): 301-8.
[http://dx.doi.org/10.1016/j.alit.2018.03.008] [PMID: 29759659]
[13]
Moingeon P, Mascarell L. Induction of tolerance via the sublingual route: mechanisms and applications. Clin Dev Immunol 2012.2012623474
[http://dx.doi.org/10.1155/2012/623474] [PMID: 22110534]
[14]
Arasi S, Corsello G, Villani A, Pajno GB. The future outlook on allergen immunotherapy in children: 2018 and beyond. Ital J Pediatr 2018; 44(1): 80.
[http://dx.doi.org/10.1186/s13052-018-0519-4] [PMID: 29996875]
[15]
Shamji MH, Kappen JH, Akdis M, et al. Biomarkers for monitoring clinical efficacy of allergen immunotherapy for allergic rhinoconjunctivitis and allergic asthma: an EAACI Position Paper. Allergy 2017; 72(8): 1156-73.
[http://dx.doi.org/10.1111/all.13138] [PMID: 28152201]
[16]
Berings M, Karaaslan C, Altunbulakli C, et al. Advances and highlights in allergen immunotherapy: On the way to sustained clinical and immunologic tolerance. J Allergy Clin Immunol 2017; 140(5): 1250-67.
[http://dx.doi.org/10.1016/j.jaci.2017.08.025] [PMID: 28941667]
[17]
Bauer CS, Rank MA. Comparative efficacy and safety of subcutaneous versus sublingual immunotherapy. J Allergy Clin Immunol 2014; 134(3): 765-765e2..
[18]
Durham SR, Penagos M. Sublingual or subcutaneous immunotherapy for allergic rhinitis? J Allergy Clin Immunol 2016; 137(2): 339-349.e10.
[http://dx.doi.org/10.1016/j.jaci.2015.12.1298] [PMID: 26853126]
[19]
Bonertz A, Roberts GC, Hoefnagel M, et al. Challenges in the implementation of EAACI guidelines on allergen immunotherapy: A global perspective on the regulation of allergen products. Allergy 2018; 73(1): 64-76.
[http://dx.doi.org/10.1111/all.13266] [PMID: 28771830]
[20]
EMA Committee for Medicinal Products for human use (CHMP). London: Guideline on Allergen Products Standardization and Quality Issues 2014.
[21]
Dhami S, Nurmatov U, Arasi S, et al. Allergen immunotherapy for allergic rhinoconjunctivitis: A systematic review and meta-analysis. Allergy 2017; 72(11): 1597-631.
[http://dx.doi.org/10.1111/all.13201] [PMID: 28493631]
[22]
Okamoto Y, Fujieda S, Okano M, Hida H, Kakudo S, Masuyama K. Efficacy of house dust mite sublingual tablet in the treatment of allergic rhinoconjunctivitis: A randomized trial in a pediatric population. Pediatr Allergy Immunol 2019; 30(1): 66-73.
[http://dx.doi.org/10.1111/pai.12984] [PMID: 30281866]
[23]
Jacobsen L, Niggemann B, Dreborg S, et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy 2007; 62(8): 943-8.
[http://dx.doi.org/10.1111/j.1398-9995.2007.01451.x] [PMID: 17620073]
[24]
Des Roches A, Paradis L, Menardo JL, Bouges S, Daurés JP, Bousquet J. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. J Allergy Clin Immunol 1997; 99(4): 450-3.
[http://dx.doi.org/10.1016/S0091-6749(97)70069-1] [PMID: 9111487]
[25]
Purello-D’Ambrosio F, Gangemi S, Merendino RA, et al. Prevention of new sensitizations in monosensitized subjects submitted to specific immunotherapy or not. A retrospective study. Clin Exp Allergy 2001; 31(8): 1295-302.
[http://dx.doi.org/10.1046/j.1365-2222.2001.01027.x] [PMID: 11529901]
[26]
Pajno GB, Barberio G, De Luca F, Morabito L, Parmiani S. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy 2001; 31(9): 1392-7.
[http://dx.doi.org/10.1046/j.1365-2222.2001.01161.x] [PMID: 11591189]
[27]
Novembre E, Galli E, Landi F, et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 2004; 114(4): 851-7.
[http://dx.doi.org/10.1016/j.jaci.2004.07.012] [PMID: 15480326]
[28]
Valovirta E, Petersen TH, Piotrowska T, et al. Results from the 5-year SQ grass sublingual immunotherapy tablet asthma prevention (GAP) trial in children with grass pollen allergy. J Allergy Clin Immunol 2018; 141(2): 529-538.e13.
[http://dx.doi.org/10.1016/j.jaci.2017.06.014] [PMID: 28689794]
[29]
Marogna M, Spadolini I, Massolo A, Canonica GW, Passalacqua G. Long-lasting effects of sublingual immunotherapy according to its duration: a 15-year prospective study. J Allergy Clin Immunol 2010; 126(5): 969-75.
[http://dx.doi.org/10.1016/j.jaci.2010.08.030] [PMID: 20934206]
[30]
Tahamiler R, Saritzali G, Canakcioglu S. Long-term efficacy of sublingual immunotherapy in patients with perennial rhinitis. Laryngoscope 2007; 117(6): 965-9.
[http://dx.doi.org/10.1097/MLG.0b013e31804f8141] [PMID: 17545861]
[31]
Calderon MA, Gerth van Wijk R, Eichler I, et al. Perspectives on allergen-specific immunotherapy in childhood: an EAACI position statement. Pediatr Allergy Immunol 2012; 23(4): 300-6.
[http://dx.doi.org/10.1111/j.1399-3038.2012.01313.x] [PMID: 22594930]
[32]
Penagos M, Eifan AO, Durham SR, Scadding GW. Duration of allergen immunotherapy for long-term efficacy in allergic rhinoconjunctivitis. Curr Treat Options Allergy 2018; 5(3): 275-90.
[http://dx.doi.org/10.1007/s40521-018-0176-2] [PMID: 30221122]
[33]
Dhami S, Kakourou A, Asamoah F, et al. Allergen immunotherapy for allergic asthma: A systematic review and meta-analysis. Allergy 2017; 72(12): 1825-48.
[http://dx.doi.org/10.1111/all.13208] [PMID: 28543086]
[34]
Lin SY, Azar A, Suarez-Cuervo C, et al. Role of sublingual immunotherapy in the treatment of asthma: An updated systematic review. Int Forum Allergy Rhinol 2018; 8(9): 982-92.
[http://dx.doi.org/10.1002/alr.22152] [PMID: 29885036]
[35]
Penagos M, Passalacqua G, Compalati E, et al. Metaanalysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age. Chest 2008; 133(3): 599-609.
[http://dx.doi.org/10.1378/chest.06-1425] [PMID: 17951626]
[36]
Nolte H, Bernstein DI, Nelson HS, et al. Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial. J Allergy Clin Immunol 2016; 138(6): 1631-8.
[http://dx.doi.org/10.1016/j.jaci.2016.06.044] [PMID: 27521719]
[37]
AHRQ, Lin YS. March 2018. Publication No. 17(18)-EHC029-EF.
[38]
Di Rienzo V, Cadario G, Grieco T, et al. Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, open, parallel-group study. Ann Allergy Asthma Immunol 2014; 113(6): 671-673.e1.
[http://dx.doi.org/10.1016/j.anai.2014.09.009] [PMID: 25304342]
[39]
Kopp MV. Role of immunmodulators in allergen-specific immunotherapy. Allergy 2011; 66(6): 792-7.
[http://dx.doi.org/10.1111/j.1398-9995.2011.02553.x] [PMID: 21332502]
[40]
Caffarelli C, Cardinale F, Povesi-Dascola C, Dodi I, Mastrorilli V, Ricci G. Use of probiotics in pediatric infectious diseases. Expert Rev Anti Infect Ther 2015; 13(12): 1517-35.
[http://dx.doi.org/10.1586/14787210.2015.1096775] [PMID: 26496433]
[41]
van de Griendt EJ, Tuut MK, de Groot H, Brand PLP. Applicability of evidence from previous systematic reviews on immunotherapy in current practice of childhood asthma treatment: a GRADE (Grading of Recommendations Assessment, Development and Evaluation) systematic review. BMJ Open 2017; 7(12)e016326
[http://dx.doi.org/10.1136/bmjopen-2017-016326] [PMID: 29288175]
[42]
Akdis CA, Akdis M. Advances in allergen immunotherapy: aiming for complete tolerance to allergens. Sci Transl Med 2015; 7(280)280ps6
[http://dx.doi.org/10.1126/scitranslmed.aaa7390] [PMID: 25810310]
[43]
Pfaar O, Urry Z, Robinson DS, et al. A randomized placebo-controlled trial of rush preseasonal depigmented polymerized grass pollen immunotherapy. Allergy 2012; 67(2): 272-9.
[http://dx.doi.org/10.1111/j.1398-9995.2011.02736.x] [PMID: 22107266]
[44]
Pfaar O, Sager A, Robinson DS. Safety and effect on reported symptoms of depigmented polymerized allergen immunotherapy: a retrospective study of 2927 paediatric patients. Pediatr Allergy Immunol 2015; 26(3): 280-6.
[http://dx.doi.org/10.1111/pai.12347] [PMID: 25640879]
[45]
Halken S, Larenas-Linnemann D, Roberts G, et al. EAACI guidelines on allergen immunotherapy: Prevention of allergy. Pediatr Allergy Immunol 2017; 28(8): 728-45.
[http://dx.doi.org/10.1111/pai.12807] [PMID: 28902467]
[46]
Boyle RJ, Elremeli M, Hockenhull J, et al. Venom immunotherapy for preventing allergic reactions to insect stings Cochrane Database Syst Rev 2012. 10CD008838
[http://dx.doi.org/10.1002/14651858.CD008838.pub2] [PMID: 23076950]
[47]
Roberts G, Pfaar O, Akdis CA, et al. EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis. Allergy 2018; 73(4): 765-98.
[http://dx.doi.org/10.1111/all.13317] [PMID: 28940458]
[48]
Di Bona D, Frisenda F, Albanesi M, Di Lorenzo G, Caiaffa MF, Macchia L. Efficacy and safety of allergen immunotherapy in patients with allergy to molds: A systematic review. Clin Exp Allergy 2018; 48(11): 1391-401.
[http://dx.doi.org/10.1111/cea.13242] [PMID: 30079619]
[49]
Roberts G, Hurley C, Turcanu V, Lack G. Grass pollen immunotherapy as an effective therapy for childhood seasonal allergic asthma. J Allergy Clin Immunol 2006; 117(2): 263-8.
[http://dx.doi.org/10.1016/j.jaci.2005.09.054] [PMID: 16461125]
[50]
Zielen S, Kardos P, Madonini E. Steroid-sparing effects with allergen-specific immunotherapy in children with asthma: a randomized controlled trial. J Allergy Clin Immunol 2010; 126(5): 942-9.
[http://dx.doi.org/10.1016/j.jaci.2010.06.002] [PMID: 20624650]
[51]
Cools M, Van Bever HP, Weyler JJ, Stevens WJ. Long-term effects of specific immunotherapy, administered during childhood, in asthmatic patients allergic to either house-dust mite or to both house-dust mite and grass pollen. Allergy 2000; 55(1): 69-73.
[http://dx.doi.org/10.1034/j.1398-9995.2000.00191.x] [PMID: 10696859]
[52]
Stelmach I, Sobocińska A, Majak P, Smejda K, Jerzyńska J, Stelmach W. Comparison of the long-term efficacy of 3- and 5-year house dust mite allergen immunotherapy. Ann Allergy Asthma Immunol 2012; 109(4): 274-8.
[http://dx.doi.org/10.1016/j.anai.2012.07.015] [PMID: 23010234]
[53]
Nelson HS, Makatsori M, Calderon MA. Subcutaneous Immunotherapy and Sublingual Immunotherapy: Comparative Efficacy, Current and Potential Indications, and Warnings--United States Versus Europe. Immunol Allergy Clin North Am 2016; 36(1): 13-24.
[http://dx.doi.org/10.1016/j.iac.2015.08.005] [PMID: 26617224]
[54]
Epstein TG, Liss GM, Berendts KM, Bernstein DI. AAAAI/ACAAI Subcutaneous Immunotherapy Surveillance Study (2013-2017): Fatalities, Infections, Delayed Reactions, and Use of Epinephrine Autoinjectors. J Allergy Clin Immunol Pract 2019; 7(6): 1996-2003.e1.
[http://dx.doi.org/10.1016/j.jaip.2019.01.058] [PMID: 30776526]
[55]
Cox L, Larenas-Linnemann D, Lockey RF, Passalacqua G. Speaking the same language: The world allergy organization subcutaneous immunotherapy systemic reaction grading system. J Allergy Clin Immunol 2010; 125(3): 569-74. 574.e1-574.e7.
[http://dx.doi.org/10.1016/j.jaci.2009.10.060] [PMID: 20144472]
[56]
Petalas K, Durham SR. Allergen immunotherapy for allergic rhinitis. Rhinology 2013; 51(2): 99-110.
[http://dx.doi.org/10.4193/Rhin12.86] [PMID: 23671890]
[57]
Lee JH, Kim SC, Choi H, et al. A retrospective study of clinical response predictors in subcutaneous allergen immunotherapy with house dust mites for allergic rhinitis. Allergy Asthma Immunol Res 2018; 10(1): 18-24.
[http://dx.doi.org/10.4168/aair.2018.10.1.18] [PMID: 29178674]
[58]
Moreno C, Cuesta-Herranz J, Fernández-Távora L, Alvarez-Cuesta E. Immunotherapy safety: a prospective multi-centric monitoring study of biologically standardized therapeutic vaccines for allergic diseases. Clin Exp Allergy 2004; 34(4): 527-31.
[http://dx.doi.org/10.1111/j.1365-2222.2004.1819.x] [PMID: 15080803]
[59]
Durham SR, Emminger W, Kapp A, et al. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol 2012; 129(3): 717-725.e5.
[http://dx.doi.org/10.1016/j.jaci.2011.12.973] [PMID: 22285278]
[60]
Didier A, Worm M, Horak F, et al. Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis. J Allergy Clin Immunol 2011; 128(3): 559-66.
[http://dx.doi.org/10.1016/j.jaci.2011.06.022] [PMID: 21802126]
[61]
Rienzo VD, Minelli M, Musarra A, et al. Post-marketing survey on the safety of sublingual immunotherapy in children below the age of 5 years. Clin Exp Allergy 2005; 35(5): 560-4.
[http://dx.doi.org/10.1111/j.1365-2222.2005.02219.x] [PMID: 15898975]
[62]
Calderón MA, Simons FE, Malling HJ, Lockey RF, Moingeon P, Demoly P. Sublingual allergen immunotherapy: mode of action and its relationship with the safety profile. Allergy 2012; 67(3): 302-11.
[http://dx.doi.org/10.1111/j.1398-9995.2011.02761.x] [PMID: 22150126]
[63]
Aasbjerg K, Dalhoff KP, Backer V. Adverse events during immunotherapy against grass pollen‐induced allergic rhinitis – differences between subcutaneous and sublingual treatment. Basic Clin Pharmacol Toxicol 2015; 117(2): 73-84.
[http://dx.doi.org/10.1111/bcpt.12416] [PMID: 25968654]
[64]
Dunsky EH, Goldstein MF, Dvorin DJ, Belecanech GA. Anaphylaxis to sublingual immunotherapy. Allergy 2006; 61(10): 1235.
[http://dx.doi.org/10.1111/j.1398-9995.2006.01137.x] [PMID: 16942576]
[65]
Vovolis V, Kalogiros L, Mitsias D, Sifnaios E. Severe repeated anaphylactic reactions to sublingual immunotherapy. Allergol Immunopathol (Madr) 2013; 41(4): 279-81.
[http://dx.doi.org/10.1016/j.aller.2012.05.012] [PMID: 23253689]
[66]
Nelson HS. Multiallergen immunotherapy for allergic rhinitis and asthma. J Allergy Clin Immunol 2009; 123(4): 763-9.
[http://dx.doi.org/10.1016/j.jaci.2008.12.013] [PMID: 19217653]
[67]
[68]
Dahl R, Kapp A, Colombo G, et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006; 118(2): 434-40.
[http://dx.doi.org/10.1016/j.jaci.2006.05.003] [PMID: 16890769]
[69]
Virchow JC, Backer V, Kuna P, et al. Efficacy of a house dust mite sublingual allergen immunotherapy tablet in adults with allergic asthma: a randomized clinical trial. JAMA 2016; 315(16): 1715-25.
[http://dx.doi.org/10.1001/jama.2016.3964] [PMID: 27115376]
[70]
Caffarelli C, Coscia A, Baldi F, et al. Characterization of irritable bowel syndrome and constipation in children with allergic diseases. Eur J Pediatr 2007; 166(12): 1245-52.
[http://dx.doi.org/10.1007/s00431-006-0410-y] [PMID: 17345097]
[71]
Caffarelli C, Dascola CP, Peroni D, et al. Airway acidification in childhood asthma exacerbations. Allergy Asthma Proc 2014; 35(3): 51-6.
[http://dx.doi.org/10.2500/aap.2014.35.3740] [PMID: 24801459]
[72]
Zuberbier T, Bachert C, Bousquet PJ, et al. GA2 LEN/EAACI pocket guide for allergen-specific immunotherapy for allergic rhinitis and asthma. Allergy 2010; 65(12): 1525-30.
[http://dx.doi.org/10.1111/j.1398-9995.2010.02474.x] [PMID: 21039596]
[74]
Kaul S, May S, Lüttkopf D, Vieths S. Regulatory environment for allergen-specific immunotherapy. Allergy 2011; 66(6): 753-64.
[http://dx.doi.org/10.1111/j.1398-9995.2011.02552.x] [PMID: 21288251]
[75]
Pfaar O, van Twuijver E, Boot JD, et al. A randomized DBPC trial to determine the optimal effective and safe dose of a SLIT-birch pollen extract for the treatment of allergic rhinitis: results of a phase II study. Allergy 2016; 71(1): 99-107.
[http://dx.doi.org/10.1111/all.12760] [PMID: 26417901]
[76]
Olivier CE. The use of Allergoids and Adjuvants in Allergen Immunotherapy Arch Asthma Allergy Immunol 2017; 040-60.
[http://dx.doi.org/10.29328/journal.haard.1001006]
[77]
Weber RW. Cross-reactivity of pollen allergens: impact on allergen immunotherapy. Ann Allergy Asthma Immunol 2007; 99(3): 203-11.
[http://dx.doi.org/10.1016/S1081-1206(10)60654-0] [PMID: 17910323]
[78]
Cipriani F, Tripodi S, Panetta V, et al. Early molecular biomarkers predicting the evolution of allergic rhinitis and its comorbidities: A longitudinal multicenter study of a patient cohort. Pediatr Allergy Immunol 2019; 30(3): 325-34.
[http://dx.doi.org/10.1111/pai.13036] [PMID: 30734368]
[79]
Sastre J, Landivar ME, Ruiz-García M, Andregnette-Rosigno MV, Mahillo I. How molecular diagnosis can change allergen-specific immunotherapy prescription in a complex pollen area. Allergy 2012; 67(5): 709-11.
[http://dx.doi.org/10.1111/j.1398-9995.2012.02808.x] [PMID: 22379958]
[80]
Stringari G, Tripodi S, Caffarelli C, et al. The effect of component-resolved diagnosis on specific immunotherapy prescription in children with hay fever. J Allergy Clin Immunol 2014; 134(1): 75-81.
[http://dx.doi.org/10.1016/j.jaci.2014.01.042] [PMID: 24794684]
[81]
Martínez-Cañavate Burgos A, Torres-Borrego J, Molina Terán AB, et al. Molecular sensitization patterns and influence of molecular diagnosis in immunotherapy prescription in children sensitized to both grass and olive pollen. Pediatr Allergy Immunol 2018; 29(4): 369-74.
[http://dx.doi.org/10.1111/pai.12866] [PMID: 29369414]
[82]
Pajno GB, Bernardini R, Peroni D, et al. Clinical practice recommendations for allergen-specific immunotherapy in children: the Italian consensus report. Ital J Pediatr 2017; 43(1): 13.
[http://dx.doi.org/10.1186/s13052-016-0315-y] [PMID: 28257631]
[83]
Caffarelli C, Dondi A, Povesi Dascola C, Ricci G. Skin prick test to foods in childhood atopic eczema: pros and cons. Ital J Pediatr 2013; 39: 48.
[http://dx.doi.org/10.1186/1824-7288-39-48] [PMID: 23902622]
[84]
Caglayan Sozmen S, Povesi Dascola C, Gioia E, Mastrorilli C, Rizzuti L, Caffarelli C. Diagnostic accuracy of patch test in children with food allergy. Pediatr Allergy Immunol 2015; 26(5): 416-22.
[http://dx.doi.org/10.1111/pai.12377] [PMID: 25808316]
[85]
Senti G, von Moos S, Tay F, Graf N, Johansen P, Kündig TM. Determinants of efficacy and safety in epicutaneous allergen immunotherapy: summary of three clinical trials. Allergy 2015; 70(6): 707-10.
[http://dx.doi.org/10.1111/all.12600] [PMID: 25704072]
[86]
Senti G, Graf N, Haug S, et al. Epicutaneous allergen administration as a novel method of allergen-specific immunotherapy. J Allergy Clin Immunol 2009; 124(5): 997-1002.
[http://dx.doi.org/10.1016/j.jaci.2009.07.019] [PMID: 19733905]
[87]
Senti G, von Moos S, Tay F, et al. Epicutaneous allergen-specific immunotherapy ameliorates grass pollen-induced rhinoconjunctivitis: A double-blind, placebo-controlled dose escalation study. J Allergy Clin Immunol 2012; 129(1): 128-35.
[http://dx.doi.org/10.1016/j.jaci.2011.08.036] [PMID: 21996342]
[88]
Patterson AM, Bonny AE, Shiels WE II, Erwin EA. Three-injection intralymphatic immunotherapy in adolescents and young adults with grass pollen rhinoconjunctivitis. Ann Allergy Asthma Immunol 2016; 116(2): 168-70.
[http://dx.doi.org/10.1016/j.anai.2015.11.010] [PMID: 26706294]
[89]
Senti G, Freiburghaus AU, Larenas-Linnemann D, et al. Intralymphatic immunotherapy: Update and unmet needs. Int Arch Allergy Immunol 2019; 178(2): 141-9.
[http://dx.doi.org/10.1159/000493647] [PMID: 30391954]
[90]
Slovick A, Douiri A, Muir R, et al. Intradermal grass pollen immunotherapy increases TH2 and IgE responses and worsens respiratory allergic symptoms. J Allergy Clin Immunol 2017; 139(6): 1830-1839.e13.
[http://dx.doi.org/10.1016/j.jaci.2016.09.024] [PMID: 27773851]
[91]
Passalacqua G, Canonica GW. Local nasal specific immunotherapy for allergic rhinitis. Allergy Asthma Clin Immunol 2006; 2(3): 117-23.
[http://dx.doi.org/10.1186/1710-1492-2-3-117] [PMID: 20525156]
[92]
Hatzler L, Panetta V, Lau S, et al. Molecular spreading and predictive value of preclinical IgE response to Phleum pratense in children with hay fever. J Allergy Clin Immunol 2012; 130(4): 894-901.e5.
[http://dx.doi.org/10.1016/j.jaci.2012.05.053] [PMID: 22841010]
[93]
Möller C, Dreborg S, Ferdousi HA, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002; 109(2): 251-6.
[http://dx.doi.org/10.1067/mai.2002.121317] [PMID: 11842293]
[94]
Niggemann B, Jacobsen L, Dreborg S, et al. Five-year follow-up on the PAT study: specific immunotherapy and long-term prevention of asthma in children. Allergy 2006; 61(7): 855-9.
[http://dx.doi.org/10.1111/j.1398-9995.2006.01068.x] [PMID: 16792584]
[95]
Valovirta E, Berstad AK, de Blic J, et al. Design and recruitment for the GAP trial, investigating the preventive effect on asthma development of an SQ-standardized grass allergy immunotherapy tablet in children with grass pollen-induced allergic rhinoconjunctivitis. Clin Ther 2011; 33(10): 1537-46.
[http://dx.doi.org/10.1016/j.clinthera.2011.09.013] [PMID: 21999887]
[96]
Kristiansen M, Dhami S, Netuveli G, et al. Allergen immunotherapy for the prevention of allergy: A systematic review and meta-analysis. Pediatr Allergy Immunol 2017; 28(1): 18-29.
[http://dx.doi.org/10.1111/pai.12661] [PMID: 27653623]
[97]
Inal A, Altintas DU, Yilmaz M, Karakoc GB, Kendirli SG, Sertdemir Y. Prevention of new sensitizations by specific immunotherapy in children with rhinitis and/or asthma monosensitized to house dust mite. J Investig Allergol Clin Immunol 2007; 17(2): 85-91.
[PMID: 17460946]
[98]
Di Bona D, Plaia A, Leto-Barone MS, La Piana S, Macchia L, Di Lorenzo G. Efficacy of allergen immunotherapy in reducing the likelihood of developing new allergen sensitizations: a systematic review. Allergy 2017; 72(5): 691-704.
[http://dx.doi.org/10.1111/all.13104] [PMID: 27926981]
[99]
Ponce M, Schroeder F, Bannert C, et al. Preventive sublingual immunotherapy with House Dust Mite extract modulates epitope diversity in pre-school children. Allergy 2019; 74(4): 780-7.
[http://dx.doi.org/10.1111/all.13658] [PMID: 30394551]
[100]
Marogna M, Tomassetti D, Bernasconi A, et al. Preventive effects of sublingual immunotherapy in childhood: an open randomized controlled study. Ann Allergy Asthma Immunol 2008; 101(2): 206-11.
[http://dx.doi.org/10.1016/S1081-1206(10)60211-6] [PMID: 18727478]


open access plus

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 16
ISSUE: 2
Year: 2020
Page: [129 - 139]
Pages: 11
DOI: 10.2174/1573396315666191021104003

Article Metrics

PDF: 49
HTML: 3